Esophagogastric Cancer clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Amivantamab in People with Esophagogastric Cancer
open to eligible people ages 18 years and up
The purpose of this study is to see whether the study drug, amivantamab, is an effective treatment for people with EGFR- or MET-amplified esophagogastric cancer. The researchers will also look at whether amivantamab is a safe treatment that causes few or mild side effects in participants.
at UC Irvine
Last updated: